The Effect of Metformin on Pregnancy Outcome Among Filipino Women with Polycystic Ovary Syndrome

Main Article Content

May Uyking-Naranjo
Evan Paulo Consencino
Roberto Mirasol
Joan Tan-Garcia


Objective.To determine the effect of metformin on maternal and neonatal outcome among pregnant Filipino women with polycystic ovary syndrome (PCOS).


Methodology.This is a retrospective cohort study of PCOS women who were on metformin treatment prior to achieving pregnancy. The women were divided into two groups: women who continued metformin during pregnancy and women who discontinued metformin at the time the pregnancy was confirmed. Determination of the effect of metformin on pregnancy outcomes were analyzed using chi-square test. Multivariate regression analysis was used to determine the factors related to spontaneous abortion.


Result. A total of 101 women continued metformin during pregnancy while 60 women discontinued metformin. Women who continued metformin had lower rates of first trimester spontaneous abortion compared to those who discontinued metformin (5% versus 36.2%, p<0.001).  There was no significant difference in gestational diabetes between those who continued and discontinued metformin during pregnancy (19.0% versus 32.6%, p=0.07). Logistic regression analysis showed that only metformin during pregnancy has a protective effect on abortion (OR=0.168; 95% CI 0.048,0.592; p=0.005). The differences in neonatal outcomes between the two groups did not achieve statistical significance.


Conclusion. In Filipino women with PCOS, continuous use of metformin during pregnancy reduces the rate of first trimester spontaneous abortion


Download data is not yet available.

Article Details

How to Cite
Uyking-Naranjo, M., Paulo Consencino, E., Mirasol, R., & Tan-Garcia, J. (2014). The Effect of Metformin on Pregnancy Outcome Among Filipino Women with Polycystic Ovary Syndrome. Journal of the ASEAN Federation of Endocrine Societies, 28(1), 45. Retrieved from
Original Articles


Frank S. Polycystic ovary syndrome. N Engl J Med. 1995; 333: 853-856.

Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.J Clin Endocrinol Metab. 2000;85:2434-243.

Fauser B, TarlatzisB,RebarR,Legro R, et al.Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertility and Sterility. 2012; 97(1):0015-0282.

Hellmuth E, Damm P, Molstead-Pedersen L. Oral hypoglycemic agents in 118 diabetic pregnancies. Diabet Med. 2000;17(7):507-511.

Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol. 1992; 37: 119-125.

Dunaif A, Segal KR, Futterweit W. Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174.

De Leo V, Musacchio MC, Piomboni P, Sabatino AD. The administration of metformin during pregnancy reduces polycyctic ovary syndrome related gestation complications. Euro Jour of Obstretrics&Gyneco and Reproductive Biology. 2011;157: 63-66.

Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: A meta-analysis. Fertil Steril. 2006;86:658-663.

Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223-1236.

Moghetti P, Castello R, Negri C, Tosi F, Caputo M, Zanolin E and Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycyctic ovary syndrome: A randomized, double blind, placebo-comtrolled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol. Metab. 2000;85:139-146.

Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with polycystic ovary syndrome. Metabolism. 1999;48:511-19.

Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome. J Adol Health. 2001;29:160-69.

Piacquadio K, Hollingsworth DR, Murphy H. Effects of in-utero exposure to oral hypoglycemic drugs. Lancet. 1991;338(8771):866-869.

Vanky E, Zahlsen K, Spigset O, Carlsen SM. Placental passage of metformin in women with polycystic ovary syndrome. Fertil Steril. 2005;83:1575-1578.

Glueck CJ, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002; 77: 520-525.

Tang T, Lord JM, Norman RJ, Yasmin E, Balen A. Insulin-sensitizing drug (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndorme, oligo amenorrhoea and subinfertility. Cochrane Database Syst Rev. 2010;(1):CD003053.

Legro RS, Barnhart HX, Schlaff WD. Clomiphene, metformin, or both for infertility in the polycyctic ovary syndrome. N Engl J Med. 2007;356:551-566.

Vanky E, Stridsklev S, Heimstad R, Romundastad P. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: A randomized, controlled multicenter study. J Clin Endocrinol Metab. 2010; 95(12):E448-455.

American Diabetes Association. Metformin in Pregnancy. Diabetes Care.2006; 29:2.

Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus of infertility treatment related to polycystic ovary syndrome. Fertil Steril. 2008;89:505-522.

Glueck CJ, Philipps H, Cameron D, Sieve-Smith L. and Wang, P. Continuing metformin throughout pregnancy in women with polycyctic ovary syndrome appears to safely reduce first-trimester SAB: A pilot study. Fertil Steril. 2001;75:46-52.

Wang JX, Davies MJ and Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod. 2001;16:2606-2608.

Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J. Clin Endocrinol Metab. 2002;87:5077-511.

Norman RJ, Wang JK, Hague W. Should we continue or stop insulin-sensitizing drugs during pregnancy? Curr Opin Obstet Gynecol. 2004;16:245-250.

Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with PCOS treated with metformin. Human Reproduction. 2002;17:2858-2864.

Holte J, Gennarelli G, Wide L. et al. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. J. Clin. Endocrinol. Metab. 1998;83:1143–1150.

Mikola M, Hiilesma V, Halttunen M et al. Obstetric outcome in women with polycystic ovary syndrome. Hum Reprod. 2001;16:226-229.

Haakova L, Cibula D, Rezabek K, Hill M, Fanta M, Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod. 2003;18(7):1438-1441.

Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673-683.

Khattab S, Mohsen IA, Aboul Foutouh I, Ashmawi HS, Mohsen MN et al. Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. Gyne Endocrinol. 2011;27(10):789-793.

Palomba S, Falbo A, Orio F Jr, ZulloF.Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Fertil Steril. 2009;92(5):1646-1658.

Lilja AE, Mathiesen ER. Polycystic ovary syndrome and metformin in pregnancy.Acta obstetrician et gynecologica Scandinavica. 2006.85 (7): 861-868.

Khattab S, Mohsen IA, Ramadan A, Moaz M, AI- Inany H. Metformin reduces abortion in pregnant women with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22: 680-684.

Homburg R, Armar NA, Eshel A, Adams J, Jacobs HS. Influence of serum LH concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome.BMJ. 1998;297:1024-1026.

Fedorcsak P, Storeng R, Dale PO, Tanbo T, Abyholm T. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstetric Gynecology Scand. 2000;79:43-48.

Jakubowicz DJ, Seppälä M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein concentration and enhances uterine vascularity and blood flow in the PCOS. J Clin Endocrin Metab. 2001;86:1126-1133.

Yu-Mallen L, Tan-Garcia J, Gaston J, Quimpo J. Prevalence of insulin resistance as determined by HOMA assessment with PCOS at St. Luke’s Medical Center: Phil. J. Internal Medicine. 2004;42:233-241.

Gilbert C, Valois M, Koren G. Pregnancy outcome after first-trimester exposure to metformin: A meta-analysis. Fertil Steril. 2006;86:658-663.

Legro R. Metformin during Pregnancy in Polycystic Ovary Syndrome: Another Vitamin Bites the Dust. J. Clin Endocrinol Metab. 2010;95(12):5199-5202.

Lo J, Feigenbaum S, Escobar G. Increased Prevalence of Gestational Diabetes Mellitus Among Women with Diagnosed Polycystic Ovary Syndrome: A population-based study. Diabetes Care. 2006; 29: 1915-1917.

Koren G, Gilbert C, Valois M. Metformin use during first trimester of pregnancy. Is it safe? An Fam Physician. 2006;52:171-172.

Sohrabvand F, Shariat M, Haghollahi F, Bagheri B. Effect of metformin on miscarriage in pregnant patients with polycystic ovary syndrome. West Indian Med J. 2009; 58(5):433-436.

Most read articles by the same author(s)

1 2 > >>